Flomics introduces a liquid biopsy with cell-free long RNAs (cfRNAs) for the early detection of complex diseases, such as cancer. From a simple blood draw, an asymptomatic individual has the chance to be screened in a minimally invasive way and to understand if he/she needs to move on to more complex exploratory analysis. This is particularly important for individuals with >50 years of age, familiars of cancer patients or high-risk populations, e.g. smokers.
In order to help in the current pandemic we are living in, Flomics has joined forces with international biotech partners, specialized in Next Generation Sequencing tests, to develop a cloud-based data analysis solution for COVID19 detection and research. Combining the unique features of the different experimental sequencing kits available for SARS-CoV-2 detection (either metagenomics or ampicon based), we maximize the information extracted from each single experiment performed in a reliable, sensitive and automated way.
Our platform helps hospitals, clinics and research laboratories in transforming raw data into interpretable clinical information that will help manage this pandemic, without the need for computational infrastructures or bioinformatics expertise
Our skills are complemented by our stellar advisory board: Albert Abad, medical oncologist with vast experience in diagnosis; Rory Johnson, expert in RNA and diseases; Alan Barrel, expert in business and internationalization.
We offer end-to-end solutions for hospitals and researchers who want to implement Next-generation sequencing (NGS) data in their research or clinical practice. From molecular protocol definition and implementation to personalized reporting and data analysis.
Our speciality is liquid biopsies with cell-free RNA but we are flexible and adapt to our collaborator needs.
To help healthcare providers fighting the COVID-19 pandemic we developed a specific cloud-based platform that can analyse NGS data remotely, in the cloud, without the need to learn bioinformatics.
More info: https://www.flomics.com/covid19/
We developed optimized protocols to generate meaningful and reproducible NGS data from any kind of sample, especially degraded and challenging samples such as human fluids samples.
Our cloud-based platform is fast, scalable and intuitive in order to be used by anyone independently of the level of knowledge in bioinformatics.
We have on-going collaboration with top-level international hospitals that give us access to patients and clinical information that help us design our solutions.
La startup Flomics recibe una inversión de 1 millón de euros para impulsar su proyecto de detección precoz del cáncer
Flomics Biotech SL
Flomics Biotech, finalista a los Global Startup Awards
Flomics Biotech SL
Flomics COVID19 NGS platform update
Flomics Biotech SL
Flomics ha sido seleccionada para el programa EIT Health Bridgehead
Flomics Biotech SL
Flomics Biotech, a startup from the Barcelona Biomedical Research Park (PRBB) and member of the Barcelona Health Hub (BHH)
Flomics Biotech SL
Oportunidad de inversión de Flomics
Flomics Biotech SL
Flomics will present at 'ENRICH in Brazil: COVID-19: International Cooperation in STI in the Health Sector in Brazil and Europe'
Flomics Biotech SL
Fully automated solution for SARS-CoV-2 NGS-based testing data analysis
Flomics Biotech SL
Flomics announces a partnership with Lifebit
Flomics Biotech SL
Flomics COVID-19 NGS platform
Flomics Biotech SL
